|Systematic (IUPAC) name|
|Molecular mass||261.3097 g/mol|
|(what is this?)|
Delucemine (NPS-1506) is a drug which acts as an NMDA antagonist and a serotonin reuptake inhibitor, and has neuroprotective effects. It was originally investigated for the treatment of stroke but is now being studied as a potential antidepressant. It is currently in clinical trials.
Condensation of 3,3-difluorobenzophenone with the lithio reagent from acetonitrile yields the benzydrol. The nitrile group is then reduced to the corresponding amine by means of diborane. Treatment with acid leads to loss of the tertiary hydroxyl group and formation of the olefin. The double bond is reduced by catalytic hydrogenation. The primary amino group can then be converted to the N-methyl derivative by any of a number of procedures, such as, treatment with formaldehyde and formic acid. Then the NMDA receptor antagonist delucemine is obtained.
- NPS Pharmaceuticals Inc NPSP Quarterly Report
- Moe, S. T.; Smith, D. L.; By, K.; Egan, J. A.; Filer, C. N. (1998). "Synthesis of 3,3-bis(3-fluorophenyl)-[2,3-3H2]-1-propanamine hydrochloride ([3H2]-NPS 846·HCl): A novel ligand for the NMDA receptor". Journal of Labelled Compounds and Radiopharmaceuticals 41 (6): 535. doi:10.1002/(SICI)1099-1344(199806)41:6<535::AID-JLCR101>3.0.CO;2-P.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|